Suramin in Treating Patients With Recurrent Bladder Cancer

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

NCT05687721 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin

NCT00234039 ·Status: COMPLETED ·Phase: PHASE2

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

NCT05496192 ·Status: WITHDRAWN ·Phase: PHASE2

Drug Screening Using IMD in Bladder Cancer

NCT06204614 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1

Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.

NCT00191711 ·Status: COMPLETED ·Phase: PHASE2

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593 ·Status: COMPLETED ·Phase: PHASE1

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT01314664 ·Status: TERMINATED

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

NCT05710848 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

NCT01328574 ·Status: COMPLETED ·Phase: PHASE2

S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

NCT00445601 ·Status: COMPLETED ·Phase: PHASE3

VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

NCT02371447 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract

NCT00315237 ·Status: COMPLETED ·Phase: PHASE3

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT04887831 ·Status: TERMINATED ·Phase: PHASE2

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

NCT03759496 ·Status: UNKNOWN ·Phase: PHASE2

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

NCT00003129 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00003701 ·Status: COMPLETED ·Phase: PHASE3

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

NCT01316874 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

NCT00042887 ·Status: TERMINATED ·Phase: PHASE3

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

NCT04701918 ·Status: COMPLETED ·Phase: PHASE2

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

NCT06493370 ·Status: RECRUITING ·Phase: PHASE2

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

NCT02007005 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

NCT02710734 ·Status: COMPLETED ·Phase: PHASE2

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

NCT06696794 ·Status: RECRUITING ·Phase: PHASE3